AC Immune SA reported its financial results for the quarter ended September 30, 2025, showing a net loss of CHF 15.9 million (approximately $19.8 million) compared with a net income of CHF 5.5 million in the same period last year.
Revenue for the quarter fell to CHF 939,000 (about $1.03 million), a 96% drop from CHF 25.5 million in Q3 2024 and a miss of the consensus estimate of $1.52 million.
The company attributed the loss to the absence of a CHF 24.6 million milestone payment received in Q3 2024 from Janssen Pharmaceuticals, as well as ongoing costs associated with its pipeline prioritization and workforce reduction program.
AC Immune confirmed that its strategic review, which sharpened focus on three Phase 2 active immunotherapy programs and small‑molecule neurodegenerative disease assets, has cut headcount by roughly 30% and extended the company’s cash runway to the end of Q3 2027, excluding future milestone payments.
Management highlighted progress in its Alzheimer’s program ACI‑35.030, for which data were published in eBioMedicine, and the Parkinson’s VacSYn trial of ACI‑7104.056, for which interim results are expected later this quarter. The company also plans to file an IND for the small‑molecule NLRP3 inhibitor ACI‑19764 and to begin IND‑enabling studies for a Morphomer‑Tau aggregation inhibitor by year‑end 2025.
The company’s cash balance stood at CHF 108.5 million as of September 30, 2025, providing sufficient liquidity to support operations through Q3 2027 under the current guidance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.